RT Journal Article
T1 HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis.
A1 Robin, Marie
A1 Porcher, Raphael
A1 Ruggeri, Annalisa
A1 Blaise, Didier
A1 Wolschke, Christine
A1 Koster, Linda
A1 Angelucci, Emanuele
A1 Stolzel, Friedrich
A1 Potter, Victoria
A1 Yakoub-Agha, Ibrahim
A1 Koc, Yener
A1 Ciceri, Fabio
A1 Finke, Jurgen
A1 Labussiere-Wallet, Helene
A1 Pascual-Cascon, Maria Jesus
A1 Verbeek, Mareike
A1 Rambaldi, Alessandro
A1 Cornelissen, Jan J
A1 Chevallier, Patrice
A1 Radia, Rohini
A1 Nagler, Arnon
A1 Fegueux, Nathalie
A1 Gluckman, Eliane
A1 de-Witte, Theo
A1 Kroger, Nicolaus
K1 HLA-mismatched donor
K1 Haploidentical transplant
K1 MDS
K1 Myelodysplastic syndrome
AB Recently, haploidentical transplantation (haplo) using post-transplant cyclophosphamide (PTCy) has been reported to give very encouraging results in patients with hematological malignancies. Patients who have no HLA-matched donor currently have the choice between a mismatched unrelated donor, an unrelated cord blood (CB) donor, and a haploidentical related donor. The aim of our study is to compare the outcome of patients with myelodysplastic syndrome (MDS) who have been transplanted from a haploidentical donor using PTCy, an HLA-mismatched unrelated donor (marrow or peripheral blood stem cells), or an unrelated mismatched CB donor. A total of 833 MDS patients from the European Group for Blood and Marrow Transplantation (EBMT) registry, transplanted between 2011 and 2016, were identified. The potential benefit of haplo was compared with mismatched unrelated and CB donors in an adjusted and weighted model taking into account potential confounders and other prognostic variables. Haplo was at lower risk of acute graft-versus-host disease (GVHD) than mismatched unrelated donor (P = .010) but at similar risk than CB. Progression-free survival was better after haplo (versus mismatched unrelated, P = .056; versus CB, P = .003) and overall survival tended to be superior after haplo (versus mismatched unrelated, P = .082; versus CB, P = .002). Nonrelapse mortality was not significantly different between haplo and mismatched unrelated donors. Relapse risk was not influenced by the type of donor. In conclusion, patients with MDS from the EBMT registry receiving hematopoietic stem cell transplantation from a haplo donor have significantly better outcome than those receiving hematopoietic stem cell transplantation from a CB donor and at least similar or better outcome than with a mismatched unrelated donor. Prospective studies comparing the type of donors will be needed to confirm this assumption.
PB Elsevier
YR 2018
FD 2018-08-23
LK http://hdl.handle.net/10668/12892
UL http://hdl.handle.net/10668/12892
LA en
NO Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, et al. HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. Biol Blood Marrow Transplant. 2019 Jan;25(1):114-120.
DS RISalud
RD Apr 9, 2025